36 results on '"Okuma, Hitomi Sumiyoshi"'
Search Results
2. Trop-2 expression and the tumor immune microenvironment in cervical cancer
3. Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy
4. High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study
5. Integrated analysis of two phase 2 trials of nivolumab in metastatic rare solid cancer with dMMR or pMMR (MASTER KEY sub-studies: ROCK and ROLL trial).
6. The Selangor Consensus: strengthening clinical trials for local public health in the Western Pacific
7. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer
8. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer
9. Supplementary Table S4 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
10. Supplementary Figure S2 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
11. Supplementary Table S3A-B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
12. Data from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
13. Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
14. A new era of the Asian clinical research network: a report from the ATLAS international symposium
15. Molecular pathology quality control in Southeast Asia: Results of a multiregional quality assurance study from MASTER KEY Asia
16. Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
17. 2022-RA-793-ESGO TROP-2 expression and the tumor immune-microenvironment in cervical cancer
18. High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: A retrospective study
19. Additional file 2 of High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study
20. Additional file 1 of High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study
21. High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer
22. Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers
23. Potentially targetable alterations identified in circulating tumor DNA (ctDNA) from patients (pts) with advanced rare cancers.
24. ROCK Trial (NCCH1709): Nivolumab monotherapy in Rare cancer patients with mismatch repair deficiency biomarker: phase II
25. Targeted-sequencing in rare cancers and the impact on patient treatment.
26. Circulating tumor DNA molecular profiling in rare cancer patients from the MASTER KEY Project.
27. MASTER KEY project: A basket/umbrella trial for rare cancers in Japan.
28. P2-243 - ROCK Trial (NCCH1709): Nivolumab monotherapy in Rare cancer patients with mismatch repair deficiency biomarker: phase II
29. Disseminated herpes zoster infection initially presenting with abdominal pain in patients with lymphoma undergoing conventional chemotherapy: A report of three cases
30. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
31. Trends in the needs and clinical utility of comprehensive genomic profiling test in rare cancers before and after the National Health Insurance coverage in Japan.
32. An Asian multi-regional registry study of rare cancers: The MASTER KEY ASIA and MASTER KEY Japan projects.
33. Exploratory novel biomarker and resistance mechanism of milademetan, an MDM2 inhibitor, in amplified MDM2 intimal sarcoma from an open-label phase 1b/2 trial (NCCH1806/MK004).
34. Planning and Implementing Master Protocol Trials in Japan: Key Considerations of the Japanese Guideline.
35. [Ⅲ.MASTER KEY Project-A Platform Study for Rare Cancers].
36. Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.